Skip to content
Screener

Alumis Inc. ALMS Total Revenue

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$12.97B+5.7%
Amgen logo
AmgenAMGN
$10.05B+9.5%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$1.63M-8.3%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$0—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$266.04M+25.9%
Immunome logo
ImmunomeIMNM
$0-100%

Segments

By product

See full
Collaboration Revenue$1.7M-37.0%
License$0—

By segment

See full
Single Reportable$1.66M-37.7%

Other financials

Income statement

See full
Operating income-$148.9M-5.9%
Net income-$142.2M-340%
EPS (diluted)-$1.11-244%

Balance sheet

See full
Cash & equivalents$63.7M-58.0%
Total debt$36.4M-6.1%
Total equity$452.2M-6.8%
Total assets$560.6M-8.2%

Cash flow

See full
Operating cash flow-$81.5M+23.4%
CapEx$237.0K-61.5%
Free cash flow-$81.7M+23.6%

Valuation

See full
Market cap$933.23M+126%
Enterprise value$905.95M+136%
P/S126.2×—

Profitability

See full
Operating margin-6,204.4%—
Net margin-5,933.5%—
FCF margin-4,755.3%—

Returns & leverage

See full
Return on equity-93.6%—
Debt / equity0.1×0.0×
Current ratio6.7×+0.7×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Alumis Inc.’s 10-Q, filed August 13, 2026.

Filed
Aug 13, 2026, 4:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001847367-26-000018
(in thousands, except share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue:
License revenue———$17,389
Collaboration revenue1,6622,6663,4032,666
Total revenue1,6622,6663,40320,055
Operating expenses:
Research and development expenses, including related party expenses of $399, $259, $465 and $521 for the three and six months ended June 30, 2026 and 2025, respectively85,337108,755166,877205,377
General and administrative expenses23,35634,45041,96656,745
Intangible assets impairment loss41,824—41,824—

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s total revenue?
Alumis Inc. (ALMS) reported total revenue of $1.66M in Q2 2026.
How has Alumis Inc.'s total revenue changed year-over-year?
Alumis Inc.'s total revenue decreased by 37.7% year-over-year, from $2.67M to $1.66M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Alumis Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude